Skip to main content
S&P 5007,757.17+0.58%DOW52,856.09+0.69%NASDAQ26,702.86+1.05%BTC$84,192.00+1.31%ETH$2,474.04+0.74%GOLD$4,133.80-0.39%OIL$98.06+0.94%
Smart Investors Daily
SID Premium
MI

NASDAQ · MIST

Milestone Pharmaceuticals Inc.

Healthcare · Biotechnology

$0.70

Down-$0.02 (-3.23%)

Updated Oct 22, 2026, 4:39 AM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
252.53M
P/E ratio
-6.21
Dividend yield
0.00%
52-week range
$0.70 – $2.34
Volume
673.28K
Avg. volume
2.14M

Price performance · MIST

MIST price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 21, 2026

MIST closed at $0.70 after 21 trading sessions, down 19.34% for the selected period.

Last close
$0.70
Period change
-19.34%
Period low
$0.70
Period high
$0.87
Daily close
View OHLC price history
MIST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 21, 2026$0.72$0.7279$0.695$0.6953673.28K
Oct 20, 2026$0.70$0.7449$0.70$0.7185502.31K
Oct 19, 2026$0.719$0.7399$0.6961$0.7001669.89K
Oct 16, 2026$0.80$0.80$0.704$0.7073980.76K
Oct 15, 2026$0.7862$0.7994$0.752$0.79451.04M
Oct 14, 2026$0.7613$0.8035$0.7501$0.7879807.12K
Oct 13, 2026$0.7924$0.8109$0.751$0.76581.2M
Oct 12, 2026$0.78$0.8141$0.74$0.80551.17M
Oct 9, 2026$0.72$0.774$0.7075$0.7651.23M
Oct 8, 2026$0.769$0.769$0.7094$0.71211.39M
Oct 7, 2026$0.758$0.77$0.725$0.7572893.57K
Oct 6, 2026$0.80$0.815$0.7605$0.76421.4M
Oct 5, 2026$0.82$0.8234$0.77$0.77941.08M
Oct 2, 2026$0.8159$0.8308$0.7921$0.8097769.55K
Oct 1, 2026$0.88$0.8965$0.8101$0.8157725.59K
Sep 30, 2026$0.838$0.8975$0.82$0.86571.27M
Sep 29, 2026$0.783$0.8279$0.7799$0.82933.57K
Sep 28, 2026$0.7809$0.8199$0.78$0.7954419.54K
Sep 25, 2026$0.80$0.815$0.7521$0.78841.27M
Sep 24, 2026$0.8799$0.8799$0.78$0.79492.33M
Sep 23, 2026$0.925$0.925$0.8506$0.8621.53M

Latest MIST news

The latest Smart Investors Daily articles mentioning MIST.

Stock researchCompany · Overview

MIST research

Overview

Company profile and research snapshot.

Company profile

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
MIST recent ratings
DateFirmRatingTarget
Sep 3, 2026HC Wainwright & Co.Buy—
Aug 20, 2026Cantor FitzgeraldOverweight—
May 14, 2026Wells FargoOverweight—
Jan 6, 2026HC Wainwright & Co.Buy—
Dec 16, 2025Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVRMONTREAL and CHARLOTTE, N.C., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the first European patient has been enrolled in ReVeRA-301, its ongoing Phase 3 pivotal trial evaluating etripamil

Yahoo · Sep 24, 2026

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of EtripamilMONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Montreal Heart Institute, recently activated as the first Canadian clinical trial site for the ReVeRA-301 Phase 3 pivotal tri

Yahoo · Sep 3, 2026

Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States

Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone Pharmaceuticals MONTREAL and CHARLOTTE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that China’s National Medical Products Adminis

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By